TAS-102: more than an antimetabolite

被引：7
|
作者：
Peters, Godefridus J. [1 ]
Bijnsdorp, Irene V. [2 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Urol, NL-1007 MB Amsterdam, Netherlands
来源：
LANCET ONCOLOGY | 2012年 / 13卷 / 12期
关键词：
ENDOTHELIAL-CELL MIGRATION; THYMIDINE PHOSPHORYLASE; COLORECTAL-CANCER; TRIFLUOROTHYMIDINE; ACTIVATION; INHIBITOR;
D O I：
10.1016/S1470-2045(12)70426-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E518 / E519
页数：2
相关论文
共 50 条
  • [1] A novel antimetabolite: TAS-102 for metastatic colorectal cancer
    Miyamoto, Yuji
    Lenz, Heinz-Josef
    Baba, Hideo
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (03) : 355 - 365
  • [2] TAS-102: a novel antimetabolite for the 21st century
    Uboha, Nataliya
    Hochster, Howard S.
    [J]. FUTURE ONCOLOGY, 2016, 12 (02) : 153 - 163
  • [3] Disappointing results for TAS-102
    Gourd, Katherine
    [J]. LANCET ONCOLOGY, 2022, 23 (08): : 988 - 988
  • [4] A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
    Emura, T
    Murakami, Y
    Nakagawa, F
    Fukushima, M
    Kitazato, K
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2004, 13 (04) : 545 - 549
  • [5] TAS-102 an Emerging Oral Fluoropyrimidine
    Chen, Jiezhong
    Han, Mei
    Saif, Muhammad Wasif
    [J]. ANTICANCER RESEARCH, 2016, 36 (01) : 21 - 26
  • [6] TAS-102 and the quest for predictive biomarkers
    van der Velden, Daphne L.
    Opdam, Frans L.
    Opdam, Frans L.
    [J]. ESMO OPEN, 2017, 2 (04)
  • [7] Prognostic stratification of TAS-102 treatment
    Goncalves, M.
    Teixeira, C.
    Almeida, C.
    Freitas, M.
    Couto, M.
    Lemos, T.
    Rego, I.
    Fernandes, C.
    Sarmento, C.
    Tavares, N.
    Barbosa, M.
    Meireles, S.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S146 - S146
  • [8] FDA Approval Summary: TAS-102
    Marcus, Leigh
    Lemery, Steven J.
    Khasar, Sachia
    Wearne, Emily
    Helms, Whitney S.
    Yuan, Weishi
    He, Kun
    Cao, Xianhua
    Yu, Jingyu
    Zhao, Hong
    Wang, Yaning
    Stephens, Olen
    Englund, Erika
    Agarwal, Rajiv
    Keegan, Patricia
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (12) : 2924 - 2927
  • [9] TAS-102 in metastatic colorectal cancer
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2018, 19 (01): : E18 - E18
  • [10] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Kiyoaki Sugiura
    Yuki Seo
    Takayuki Takahashi
    Hideyuki Tokura
    Yasuhiro Ito
    Motomu Tanaka
    Norihiro Kishida
    Yusuke Nishi
    Yoshihiko Onishi
    Hikaru Aoki
    [J]. BMC Gastroenterology, 21
12345